Invention Grant
- Patent Title: Inhibitors of DNMT1 as anticancer therapeutic agents
-
Application No.: US17250330Application Date: 2019-07-09
-
Publication No.: US11518779B2Publication Date: 2022-12-06
- Inventor: Peter Charles Tyler , Farah Lamiable-Oulaidi , Anthony David Woolhouse , Shivali Ashwin Gulab , Karl Jürgen Shaffer , Ashna Ashneen Khan , Douglas Ronald Crump , Vern L. Schramm , Quan Du
- Applicant: Victoria Link Limited , Albert Einstein College of Medicine , Timothy Dravitzki
- Applicant Address: NZ Wellington; US NY Bronx; NZ Porirua
- Assignee: Victoria Link Limited,Albert Einstein College of Medicine,Timothy Dravitzki
- Current Assignee: Victoria Link Limited,Albert Einstein College of Medicine,Timothy Dravitzki
- Current Assignee Address: NZ Wellington; US NY Bronx; NZ Porirua
- Agency: Fox Rothschild LLP
- International Application: PCT/NZ2019/050080 WO 20190709
- International Announcement: WO2020/013712 WO 20200116
- Main IPC: C07H19/16
- IPC: C07H19/16
Abstract:
Provided herein are inhibitors of DNA methyltransferase 1 (an enzyme responsible for the maintenance of DNA CpG methylation marks in human cells) and their use for inhibiting DNA methyltransferase 1. The invention relates to compounds, pharmaceutical compositions, and methods for inhibiting DNA methyltransferase 1. The inhibitors are compounds of the general formula:
Public/Granted literature
- US20210206795A1 INHIBITORS OF DNMT1 AS ANTICANCER THERAPEUTIC AGENTS Public/Granted day:2021-07-08
Information query
IPC分类:
